Condition
Astrocytoma, Grade II
Total Trials
5
Recruiting
0
Active
0
Completed
2
Success Rate
40.0%-47% vs avg
Key Insights
Highlights
Success Rate
40% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
60.0%
3 terminated out of 5 trials
Success Rate
40.0%
-46.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
150%
3 of 2 completed with results
Key Signals
3 with results40% success
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 2 (2)
Trial Status
Terminated3
Completed2
Trial Success Rate
40.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT02549833Phase 1Completed
Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma
NCT04304300CompletedPrimary
Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes
NCT02924038Phase 1Terminated
A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
NCT03906448Phase 2TerminatedPrimary
FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma
NCT01836549Phase 2Terminated
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Showing all 5 trials